oral.glp 1 Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill For Weight

(See our interactive map for provider locations across Salt Lake City.)

For women, particularly postmenopausal patients with increased cardiovascular risk, this low-dose regimen could serve as a preventive metabolic therapycomplementing hormone optimization, nutrition, and exercise to extend healthspan and protect against heart disease, the leading cause of death in women

Jin ES, Malloy CR, Sharma G, Finn E, Fuller KN, Reyes YG, et al

Across the three doses of tirzepatide, all patients achieved this composite endpoint in a significantly greater percent compared to patients on semaglutide, with a satisfactory safety profile [25]

Impact on body image and clothing GLP-1 use has been linked to improved body image, greater confidence, and changes in how patients present themselves and spend on clothing

3 Obesity currently affects over one billion individuals worldwide and, in 2024, was directly implicated in over 3.7 million deaths